Raheel A Raja, Kjeld Schmiegelow, Birgitte K Albertsen, Kaie Prunsild, Bernward Zeller, Goda Vaitkeviciene, Jonas Abrahamsson, Mats Heyman, Mervi Taskinen, Arja Harila-Saari, Jukka Kanerva, Thomas L Frandsen
L-asparaginase is an important drug in the treatment of childhood acute lymphoblastic leukaemia (ALL). Treatment is associated with several toxicities, including acute pancreatitis. Clinical course, presentation, re-exposure to L-asparginase after pancreatitis and risk of recurrent pancreatitis within an asparaginase-intensive protocol has been poorly reported. Children (1-17 years) on the ongoing Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL2008 protocol with asparaginase-associated pancreatitis (AAP) diagnosed between 2008 and 2012 were identified through the online NOPHO ALL toxicity registry...
April 2014: British Journal of Haematology